Toxicity Management and Efficacy Evaluation of BCMA-CART in the Treatment of Relapsed and Refractory Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2022.02.024
- Author:
Xiao-Yuan ZHANG
1
;
Han-Yi DING
1
;
Dong-Xu GANG
1
;
Xiao-Yu HE
1
;
Yong-Yong MA
1
;
Hong-Lan QIAN
1
;
Xuan-Ru LIN
1
;
Chong-Yun XING
1
;
Yu ZHANG
1
;
Song-Fu JIANG
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang Province, China.
2. Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang Province, China,E-mail: Songfu.Jiang@wzhospital.cn.
- Publication Type:Journal Article
- Keywords:
B cell maturation antigen;
chimeric antigen receptor T cells;
cytokine release syndrome;
multiple myeloma;
relapsed and refractory
- MeSH:
B-Cell Maturation Antigen;
Humans;
Immunotherapy, Adoptive/adverse effects*;
Multiple Myeloma/therapy*;
Receptors, Chimeric Antigen;
Remission Induction
- From:
Journal of Experimental Hematology
2022;30(2):466-475
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the toxicity management and efficacy evaluation of BCMA-chimeric antigen receptor T cells(CART) in the treatment of relapsed and refractory multiple myeloma (MM).
METHODS:The efficacy and adverse reactions of 21 patients with MM who received BCMA-CART treatment at the First Affiliated Hospital of Wenzhou Medical University from December 2017 to September 2020 were evaluated, and the efficacy assessment and survival analysis for high-risk patients and non-high-risk patients were evaluated.
RESULTS:After infusion of BCMA-CART cells in 21 MM patients, the number of effective cases was 17, of which the complete remission (sCR/CR) was 10, and the partial remission (VGPR/PR) was 7. The median OS time for all patients was 19.4 months, and the median PFS time was 7.9 months. The number of patients with extramedullary disease(EMD), high-risk genetics, and ISS stage Ⅲ were 5, 15 and 8, and the effective number was 3, 11 and 6, respectively. The treatment of 3 patients without high-risk factors was effective. The median OS and median PFS of patients with EMD were 14.2 and 2.5 months, respectively, which were shorter than those of patients without EMD (19.4 months and 8.9 months, respectively). The median OS and median PFS of patients with high-risk cytogenetic factors and ISS Ⅲ were not significantly different from those of non-high-risk patients. Cytokine release syndrane (CRS) occurred in 20 patients, of which 14 cases were Grade 1 CRS, while 6 were Grade 2, no CRS of Grade 3 or above occurred. IL-6 receptor inhibitors were used in 9 patients. All CRS were controlled effectively, and no patients had neurological toxicity.
CONCLUSION:BCMA-CART is a certain curative effect in the treatment of relapsed and refractory multiple myeloma, and the adverse reactions can be well controlled through close monitoring and timely treatment.
